Evidence map›Paper›PMID 27378305›Full record

ArticleJournal of translational medicine2016

LRG1 downregulation in allergic airway disorders and its expression in peripheral blood and tissue cells.

Lijing Hao, Hua Xie, Bin Zhang, Dong Chen, Shufen Wang, Huiyun Zhang, Shaoheng He

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. The critical role of LRG1 in pathological fibrosis.Journal of molecular medicine (Berlin, Germany) · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lijing HaoAllergy and Clinical Immunology Research Centre, The First Affiliated Hospital of Jinzhou Medical University, No. 2, Sect. 5, Renmin Street, Guta District, Jinzhou, 121001, Liaoning, People's Republic of China.
Hua XieAllergy Clinic, The General Hospital of Shenyang Military Region, Shenyang, 110016, Liaoning, People's Republic of China.
Bin ZhangDepartment of Dentistry, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, 121001, Liaoning, People's Republic of China.
Dong ChenAllergy and Clinical Immunology Research Centre, The First Affiliated Hospital of Jinzhou Medical University, No. 2, Sect. 5, Renmin Street, Guta District, Jinzhou, 121001, Liaoning, People's Republic of China.
Shufen WangAllergy and Clinical Immunology Research Centre, The First Affiliated Hospital of Jinzhou Medical University, No. 2, Sect. 5, Renmin Street, Guta District, Jinzhou, 121001, Liaoning, People's Republic of China.
Huiyun ZhangAllergy and Clinical Immunology Research Centre, The First Affiliated Hospital of Jinzhou Medical University, No. 2, Sect. 5, Renmin Street, Guta District, Jinzhou, 121001, Liaoning, People's Republic of China.
Shaoheng HeAllergy and Clinical Immunology Research Centre, The First Affiliated Hospital of Jinzhou Medical University, No. 2, Sect. 5, Renmin Street, Guta District, Jinzhou, 121001, Liaoning, People's Republic of China. shoahenghe@hotmail.com.
Jinzhou Medical University · CNGeneral Hospital of Shenyang Military Region · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIncreased leucine-rich α2-glycoprotein-1 (LRG1) has been observed in plasma of individuals with various diseases. However, the role of LRG1 in allergic airway disease has not been investigated.

objectiveTo explore the involvement of LRG1 in allergy and its cell origins.

methodsThe expression levels of LRG1 and its receptor transforming growth factor-beta receptor II (TGFBR2) in patients with allergic rhinitis (AR) and asthma (AS) were examined by flow cytometry, and enzyme-linked immunosorbent assay (ELISA).

resultsLRG1 and soluble TGFBR2 expression in plasma of patients with AR and AS were markedly lower than that of healthy control (HC) subjects. Large proportions of CD123 + HLA-DR-, CD16+, CD4+, CD8+, CD14+, and CD19+ cells expressed LRG1, although the percentages of LRG1+ cells in these cell populations were lower in AR and AS patients. Up to 89.8 and 15.5 % of dispersed mast cells expressed LRG1 and TGFBR2. Moreover, allergen extract exposure significantly reduced LRG1 and TGFBR2 expression in the plasma and leukocytes of patients with AR and AS.

conclusionsReduced LRG1 and TGFBR2 levels in patients with allergic airway disorders are likely caused by inhibitory actions of allergens in LRG1 producing cells. Thus, LRG1 may be a key regulatory factor of allergic responses.

Indexed as

Down-RegulationOrgan SpecificityAdolescentAdultAgedAllergensAsthmaCase-Control StudiesCell LineFemaleFlow CytometryGlycoproteinsHumansMaleMast CellsMiddle AgedAllergensGlycoproteinsLRG1 protein, humanProtein Serine-Threonine KinasesReceptors, Transforming Growth Factor betaReceptor, Transforming Growth Factor-beta Type IITryptasesAllergic airway disorderLeukocytesLRG1Mast cellsTGFBR2

Identifiers

PMID27378305
PMCPMC4932677
OpenAlexW2471617533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.